Catalyst Wire Dossier Catalyst Wire Dossier

Allo-RevCAR01-T-CD123

· AvenCell Europe GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Allo-RevCAR01-T-CD123, covering 2025-05-14 to 2025-05-14. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies [Phase 1]

See pricing